Latest News

Press Release: Amgen Announces Robust Weight Loss With MariTide in People Living With Obesity or Overweight at 52 Weeks in a Phase 2 Study

Understanding Obesity: A Complex Biological Disease

Obesity is a global public health challenge that increases the risk of many other serious diseases and conditions.1 These obesity-related conditions include type 2 diabetes, heart failure, kidney disease, obstructive sleep apnea and cardiovascular disease.2 Approximately one billion people worldwide are living with obesity3 and these numbers could rise into the billions in coming decades.4

As a complex biological disease, obesity affects different people in different ways and many therapeutic options may be necessary to fulfill the needs of all people living with obesity, overweight and related conditions. Addressing the needs of this community is a challenge that we take seriously and view as critical for public health.

In addition to our lead asset maridebart cafraglutide, also known as MariTide (formerly AMG 133), Amgen is also advancing an obesity pipeline including both oral and injectable approaches, composed of both incretin and non-incretin mechanisms. These treatment approaches are diverse and tailored to meet the dynamic needs of people who are overweight or living with obesity and related conditions, underscoring our commitment to innovation and patient care.

42.5%
In the U.S., more than two in five adults are living with obesity5
2x
The worldwide prevalence of obesity more than doubled between 1990 and 20223
~ 1 billion
The number of people worldwide living with obesity3

Science Rooted in Biology

Mechanism of Action for Our Lead Asset

Mechanism of Action for our Lead Asset, MariTide (AMG 133)
Targeting Obesity Using Biology to Enhance Behavior

The People Behind the Science

$link.Title
PEOPLE & CULTURE 09.05.2024

From Rural France to Cutting-Edge Science: Murielle Véniant-Ellison’s Journey to Obesity Research
More Stories

Patient-Guided Clinical Development

What Can We Expect from a Phase 1 Trial

What Can We Expect from a Phase 1 Trial
What is Real-World Evidence?

How Real-World Evidence Informs our Obesity Approach

Press Releases and Publications

Press Releases

November 26, 2024

Amgen Announces Robust Weight Loss With MariTide in People Living With Obesity or Overweight at 52 Weeks in a Phase 2 Study

December 1, 2022

Amgen Presents New AMG 133 Phase 1 Clinical Data at WCIRDC 2022

Research Papers

February 5, 2024

Nature Metabolism manuscript, "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings"

February 5, 2024

Corresponding "Behind the Paper" feature by Murielle Véniant-Ellison

May 18, 2021

Cell Reports Medicine article, "GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys"

October 5, 2020

Nature communications article, "Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism"

September 12, 2019

Endocrine Reviews article, "Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?"

December 19, 2018

Science Translational Medicine article, "Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models"

December 22, 2017

Nature Genetics publication, "Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity"

October 10, 2010

Nature Genetics publication, "Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index"

References

  1. GBD 2015 Obesity Collaborators; Afshin A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27.
  2. Health Risks of Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases.  https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks. Published October 30, 2023. 
  3. World Health Organization: WHO. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Published March 1, 2024. 
  4. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. 
  5. Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E-Stats. 2020. www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm.